JTT 552Alternative Names: JTT-552
Latest Information Update: 23 Jul 2009
At a glance
- Originator Japan Tobacco
- Class Antigouts
- Mechanism of Action SLC22A12 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperuricaemia
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-II for Hyperuricaemia in Japan (PO)
- 28 Nov 2006 Phase-I clinical trials in Hyperuricaemia in Japan (unspecified route)